| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834.
|
| [2] |
How JA, Jazaeri AA, Westin SN, et al. Translating biological insights into improved management of endometrial cancer[J]. Nat Rev Clin Oncol, 2024, 21(11):781-800. doi: 10.1038/s41571-024-00934-7.
pmid: 39198622
|
| [3] |
郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231. doi: 10.3760/cma.j.cn112152-20240119-00035.
|
| [4] |
Wang Y, Liu N, Guo X, et al. The immune microenvironment in endometrial carcinoma: mechanisms and therapeutic targeting[J]. Front Immunol, 2025, 16:1586315. doi: 10.3389/fimmu.2025.1586315.
|
| [5] |
de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3):374-403. doi: 10.1016/j.ccell.2023.02.016.
pmid: 36917948
|
| [6] |
Hood LE. Lessons Learned as President of the Institute for Systems Biology (2000-2018)[J]. Genomics Proteomics Bioinformatics, 2018, 16(1):1-9. doi: 10.1016/j.gpb.2018.02.002.
|
| [7] |
Mani S, Lalani SR, Pammi M. Genomics and multiomics in the age of precision medicine[J]. Pediatr Res, 2025, 97(4):1399-1410. doi: 10.1038/s41390-025-04021-0.
pmid: 40185865
|
| [8] |
Galant N, Krawczyk P, Monist M, et al. Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection[J]. Int J Mol Sci, 2024, 25(11):5893. doi: 10.3390/ijms25115893.
|
| [9] |
Molefi T, Mabonga L, Hull R, et al. From Genes to Clinical Practice: Exploring the Genomic Underpinnings of Endometrial Cancer[J]. Cancers(Basel), 2025, 17(2):320-353. doi: 10.3390/cancers17020320.
|
| [10] |
Recio F, Scalise CB, Loar P, et al. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies[J]. Gynecol Oncol, 2024, 182:63-69. doi: 10.1016/j.ygyno.2023.12.025.
pmid: 38262240
|
| [11] |
Dixit G, Gonzalez-Bosquet J, Skurski J, et al. FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways[J]. Clin Transl Med, 2023, 13(5):e1223. doi: 10.1002/ctm2.1223.
pmid: 37165578
|
| [12] |
O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study[J]. J Clin Oncol, 2022, 40(7):752-761. doi: 10.1200/JCO.21.01874.
|
| [13] |
Passarelli A, Carbone V, Pignata S, et al. Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity[J]. Gynecol Oncol, 2024, 183:61-67. doi: 10.1016/j.ygyno.2024.02.029.
pmid: 38518529
|
| [14] |
Mondal O, Kiruba B, Sudhakaran SL, et al. Navigating tumour microenvironment in endometrial carcinoma: a comprehensive review integrating immunohistochemistry, single-cell RNA-sequencing and spatial transcriptomics[J]. Front Oncol, 2025, 15:1685565. doi: 10.3389/fonc.2025.1685565.
|
| [15] |
Lee GY, Ham S, Lee SV. Brief guide to RNA sequencing analysis for nonexperts in bioinformatics[J]. Mol Cells, 2024, 47(5):100060. doi: 10.1016/j.mocell.2024.100060.
|
| [16] |
Huang Y, Zhang M, Gao Q. Mapping the tumor immune landscape: single-cell RNA sequencing in cancer immunotherapy[J]. Cancer Lett, 2025, 633:218012. doi: 10.1016/j.canlet.2025.218012.
|
| [17] |
Ren F, Wang L, Wang Y, et al. Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs[J]. Cell Death Dis, 2024, 15(8):571. doi: 10.1038/s41419-024-06960-8.
pmid: 39112478
|
| [18] |
Yu X, Xie L, Ge J, et al. Integrating single-cell RNA-seq and spatial transcriptomics reveals MDK-NCL dependent immunosuppressive environment in endometrial carcinoma[J]. Front Immunol, 2023, 14:1145300. doi: 10.3389/fimmu.2023.1145300.
|
| [19] |
Gobena S, Admassu B, Kinde MZ, et al. Proteomics and Its Current Application in Biomedical Area: Concise Review[J]. Scientific World Journal, 2024, 2024:4454744. doi: 10.1155/2024/4454744.
|
| [20] |
Yildirim OS, Yildiz P, Karaer A, et al. Exploring the protein signature of endometrial cancer: A comprehensive review through diverse samples and mass spectrometry-based proteomics[J]. Eur J Surg Oncol, 2025, 51(4):108783. doi: 10.1016/j.ejso.2024.108783.
|
| [21] |
Dou Y, Kawaler EA, Cui Zhou D, et al. Proteogenomic Characterization of Endometrial Carcinoma[J]. Cell, 2020, 180(4):729-748.e26. doi: 10.1016/j.cell.2020.01.026.
pmid: 32059776
|
| [22] |
Romano A, Rižner TL, Werner H, et al. Endometrial cancer diagnostic and prognostic algorithms based on proteomics, metabolomics, and clinical data: a systematic review[J]. Front Oncol, 2023, 13:1120178. doi: 10.3389/fonc.2023.1120178.
|
| [23] |
Dalamaga M. Clinical metabolomics: Useful insights, perspectives and challenges[J]. Metabol Open, 2024, 22:100290. doi: 10.1016/j.metop.2024.100290.
|
| [24] |
Fux E, Lenski M, Bendt AK, et al. A global perspective on the status of clinical metabolomics in laboratory medicine-a survey by the IFCC metabolomics working group[J]. Clin Chem Lab Med, 2024, 62(10):1950-1961. doi: 10.1515/cclm-2024-0550.
|
| [25] |
Wang Y, Liu Q, Sun Y, et al. Association between metabolic disorders and clinicopathologic features in endometrial cancer[J]. Front Endocrinol(Lausanne), 2024, 15:1351982. doi: 10.3389/fendo.2024.1351982.
|
| [26] |
Chen J, Lu H, Cao D, et al. Urine and serum metabolomic analysis of endometrial cancer diagnosis and classification based on ultra-performance liquid chromatography mass spectrometry[J]. Metabolomics, 2024, 20(1):18. doi: 10.1007/s11306-023-02085-9.
pmid: 38281200
|
| [27] |
Pietkiewicz D, Zaborowski MP, Plewa S, et al. Targeted Metabolomic Serum Analysis of Patients with High and Low Risk of Endometrial Cancer Recurrence and Positive and Negative Lymph Node Status[J]. Metabolites, 2025, 15(7):422-443. doi: 10.3390/metabo15070422.
|
| [28] |
Chalif J, Wang H, Spakowicz D, et al. The microbiome and gynecologic cancer: cellular mechanisms and clinical applications[J]. Int J Gynecol Cancer, 2024, 34(2):317-327. doi: 10.1136/ijgc-2023-004894.
|
| [29] |
Semertzidou A, Whelan E, Smith A, et al. Microbial signatures and continuum in endometrial cancer and benign patients[J]. Microbiome, 2024, 12(1):118. doi: 10.1186/s40168-024-01821-0.
pmid: 38951935
|
| [30] |
Yuan C, Xie K, Feng L, et al. The role and challenges of regulating endometrial microbiome in uterine health and diseases[J]. Crit Rev Microbiol, 2024, 50(5):937-954. doi: 10.1080/1040841X.2024.2320247.
|